Specialties Medical OncologyQuestion

Would you offer adjuvant avapritinib or imatinib for a high-risk, PDGFR D842V-mutated GIST after resection?

1

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

Which patient characteristics or clinical factors guide the decision to use Doxorubicin and Trabectedin as first-line treatment for metastatic or unresectable leiomyosarcoma?

How do you approach a patient with indolent, small-volume, but slowly progressive lung mets from sarcoma?

How would you incorporate abemaciclib into treatment for advanced/metastatic dedifferentiated liposarcoma if approved based on SARC041?

If PEAK (bezuclastinib + sunitinib) is approved, how would it influence your second-line treatment strategy for patients with advanced KIT-mutant GIST following imatinib failure?

What are your top takeaways in Sarcoma from ASCO 2026?

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.